- 期刊
- OpenAccess
Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
並列摘要
In the past decade, molecular-targeted drugs have been focused upon for the treatment of cancer. In 2002, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor became available in Japan for the treatment of non-small cell lung cancer (NSCLC). Over 80% of selected patients, such as EGFR mutation-positive patients, respond to gefitinib treatment; however, most patients develop acquired resistance to gefitinib within a few years. Recently, many studies have been performed to determine precisely how to select patients who will respond to gefitinib, the best timing for its administration, and how to avoid the development of acquired resistance as well as adverse drug effects. This article reviews the use of gefitinib for the treatment of NSCLC from a pharmaceutical viewpoint.
延伸閱讀
- Su, W. P., Yang, C. H., Yu, C. J., Shih, J. Y., Hsu, C., & Yang, P. C. (2005). Gefitinib Treatment for Non-Small Cell Lung Cancer-A Study Including Patients with Poor Performance Status. Journal of the Formosan Medical Association, 104(8), 557-562. https://doi.org/10.29828/JFMA.200508.0003
- Luo, Y. H., Lee, Y. C., Peng, J. W., & Chen, Y. M. (2015). Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer. 台灣癌症醫學雜誌, 2(3), 179-194. https://doi.org/10.6323/JCRP.2015.2.3.01
- Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2013). Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. Clinical Medicine Insights: Oncology, (), 85-85. https://doi.org/10.4137/CMO.S11910
- Kimura, T., Kudoh, S., & Hirata, K. (2011). Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride. Clinical Medicine Insights: Oncology, (), 23-34. https://doi.org/10.4137/CMO.S5072
- Faller, B. A., & Pandit, T. N. (2011). Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, (), 131-144. https://doi.org/10.4137/CMO.S5074